KDR and neoplasm: Although our results showed that targeting host VEGFR1+ and VEGFR2+ non-tumor cells was sufficient to inhibit tumor growth, the notion that a therapy may be more effective if it can target both the cancer cells and its microenvironment prompted us to investigate the expression patterns and clinical significance of VEGFR1 and VEGFR2 in ESCC.